Procrit Could Return To Growth Later This Year, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Anemia therapy should reverse a quarterly sales decline brought on by competition from Amgen, Johnson & Johnson maintains. Worldwide sales were up for the second quarter.